Representative index, comorbidity, and follow-up data from selected studies
| Baseline data | Comorbidity | Follow-up | Mortality | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year | First author | No of cases | HTN | DM | CHOL | CAHD | PVD | Smoke | No of cases | Mean f/u (years) | Stroke | Hemorrhage | Overall death | Death lesion growth | Death mass effect | Death stroke | Death hemorrhage | Death other |
| 1982 | Yu | 17 | ? | ? | ? | ? | ? | ? | 16 | 2.5 | ? | 0 | 10 | ? | 5 | 0 | 1 | 1 |
| 1989 | Pessin | 7 | 5 | ? | ? | ? | ? | ? | 7 | 2.1 | 0 | 0 | 3 | ? | 0 | 3 | 0 | 0 |
| 1989 | Echiverri | 13 | 4 | 2 | 0 | 3 | ? | ? | 13 | 1.6 | 3 | 0 | 5 | ? | 2 | 2 | 0 | 1 |
| 1994 | Pozzati | 16 | ? | ? | ? | ? | ? | ? | 16 | 0.3 | 2 | 2 | 3 | ? | 0 | 1 | 2 | 0 |
| 2000 | Inamasu | 17 | ? | ? | ? | ? | ? | 9 | 2.5 | 0 | 4 | 4 | ? | 0 | 0 | 4 | 0 | |
| 2008 | Passero | 156 | 100 | 18 | 57 | 15 | ? | 43 | 149 | 12.9 | 59 | 21 | 62 | 31 | ? | 24 | ? | 35 |
| 1998 | Ince | 10 | 9 | 2 | ? | ? | ? | 7 | 10 | 3.4 | ? | 0 | ? | ? | ? | ? | ? | ? |
| 2004–2005 | Mayo cohort* | 159 | 109 | 16 | 63 | 44 | 11 | 82 | 159 | 4.4 | 33 | 6 | 76 | 17 | 15 | ? | 6 | 36 |
| 2004 | Ubogu | 45 | 32 | 8 | 14 | 13 | 11 | ? | 45 | 5.3 | ? | ? | 16 | ? | 3 | 6 | 3 | 4 |
*The Mayo cohort experience is described in three separate publications.14–16
CAHD, coronary artery heart disease; CHOL, hypercholesterolemia; DM, diabetes mellitus; f/u, follow-up; HTN, hypertension; PVD, peripheral vascular disease; Smoke, smoking.